Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen

Autor:	Kazuya Hirakawa, Yoshikazu Kinoshita, Kyoichi Adachi, Akira Kawamura, Takekazu Kaji, S. Hattori, Norihisa Ishimura, Masatoshi Niigaki, T. Hashimoto, Hirofumi Fujishiro, Shunji Ishihara, H. Sato, Mamoru Watanabe
Rok vydání:	2001
Předmět:	Breath test medicine.medical_specialty Hepatology medicine.diagnostic_test biology business.industry Gastroenterology Lansoprazole Amoxicillin Helicobacter pylori biology.organism_classification Surgery Regimen Clarithromycin Internal medicine medicine Pharmacology (medical) Adverse effect business medicine.drug Antibacterial agent
Zdroj:	Alimentary Pharmacology & Therapeutics. 15:1187-1191
ISSN:	0269-2813
DOI:	10.1046/j.1365-2036.2001.01022.x
Popis:	Background : The cytoprotective agent, ecabet sodium, inhibits urease activity and growth of Helicobacter pylori. Aim : To evaluate the efficacy and safety of ecabet sodium-based eradication of H. pylori infection, compared with a lansoprazole-based regimen, in a randomized multicentre study. Subjects and methods : A total of 120 H. pylori-positive patients were assigned to one of two treatment regimens for 2 weeks: ecabet sodium 1 g b.d., amoxicillin 500 mg t.d.s. and clarithromycin 400 mg b.d. (EAC: 60 patients); or lansoprazole 30 mg (o.m.) with the same antimicrobial agents (LAC: 60 patients). Cure of infection was assessed by a 13C-urea breath test 1 month after completion of treatment. Results : One patient in the EAC group and two in the LAC group did not complete therapy because of an adverse event, and three did not undergo the 13C-urea breath test. Cure rates for the intention-to-treat, all-patients-treated and per protocol analysis in the EAC group were 85%, 86% and 88%, respectively, whereas those in the LAC group were 85%, 88% and 91%. There were no significant differences in cure rate or adverse events between the two regimens. Conclusions : Ecabet sodium in combination with amoxicillin and clarithromycin is as effective as lansoprazole-based eradication therapy for H. pylori.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::66b8a123312337c4cbd2de6997565c43 https://doi.org/10.1046/j.1365-2036.2001.01022.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.